Peregrine Pharmaceuticals (PPHM +5.6%) jumps in morning trading.
The company says data show PS-targeting antibodies (like bavituximab) "yielded enhanced anti-tumor activity in a pre-clinical model of melanoma" when paired with an anti-CTLA-4 antibody.
In a mouse model, the treatment group (i.e. the group that got the combination treatment) demonstrated "superior tumor growth inhibition than with either antibody alone with no additional toxicity following multiple treatment doses."
Here's the company's VP of preclinical research: ""The results ... demonstrate that PS-targeting antibodies can block PS-mediated immunosuppression while simultaneously activating the immune system and that these effects can greatly improve the number of subjects responding to anti-CTLA-4 immunotherapy." (PR)